SCHEMBL542855

SCHEMBL542855

CC(C)[C@@H](C(=O)O)N1C(=O)c2ccccc2C1=O

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.67
ALDH1A1 P00352 5/20 0.60
LMNA P02545 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.52
GAA P10253 2/20 0.51
POLB P06746 2/20 0.51
KMT2A Q03164 1/20 0.51
KDM4E B2RXH2 2/20 0.50
FPR1 P21462 1/20 0.50
GLA P06280 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2D6 P10635 1/20 0.50
HPGD P15428 1/20 0.50
ALOX12 P18054 1/20 0.50
NFKB1 P19838 1/20 0.50
APEX1 P27695 1/20 0.50
MAPK1 P28482 1/20 0.50
HSD17B10 Q99714 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
TSHR P16473 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30299438 1.00 TP53 (0.67) TP53ALDH1A1LMNASMN1; SMN2GAA
SCHEMBL511872 1.00 TP53 (0.67) TP53ALDH1A1LMNASMN1; SMN2GAA
SCHEMBL1171070 1.00 TP53 (0.67) TP53ALDH1A1LMNASMN1; SMN2GAA
N Phthaloyl-L-Threonine SCHEMBL5424529 0.87 TP53 (0.56) TP53ALDH1A1LMNAGAAPOLB
SCHEMBL27877368 0.87 TP53 (0.53) TP53ALDH1A1LMNASMN1; SMN2GAA
SCHEMBL13367251 0.85 TP53 (0.62) TP53ALDH1A1LMNASMN1; SMN2GAA
SCHEMBL25583418 0.85 KDM4E (0.62) TP53ALDH1A1LMNAGAAKMT2A
SCHEMBL14648862 0.84 TP53 (0.60) TP53ALDH1A1LMNASMN1; SMN2GAA
SCHEMBL12284244 0.84 TP53 (0.60) TP53ALDH1A1LMNASMN1; SMN2GAA
SCHEMBL1927731 0.84 TP53 (0.60) TP53ALDH1A1LMNASMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160046570-A1 N-ACYLOXYSULFONAMIDE AND N-HYDROXY-N-ACYLSULFONAMIDE DERIVATIVES THE JOHNS HOPKINS UNIVERSITY 2016-02-18 US claimed
US-20140235636-A1 N-ACYLOXYSULFONAMIDE AND N-HYDROXY-N-ACYLSULFONAMIDE DERIVATIVES CARDIOXYL PHARMACEUTICALS, INC. (US) 2014-08-21 US claimed
EP-2509941-A2 N-ACYLATED HYDROXYLAMINE DERIVATIVES AND O-ACYLATED HYDROXYLAMINE DERIVATIVES The Johns Hopkins University (US) 2012-10-17 EP claimed
EP-3924349-B1 AMINO ACID DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES THE ROSKAMP INST (US) 2025-06-25 EP disclosed
CN-119613485-A Preparation method of dipeptide-2 中原食品实验室 2025-03-14 CN disclosed
CN-116712561-A Antibody-drug conjugates containing an N-methyleneamide linker 杭州爱科瑞思生物医药有限公司 2023-09-08 CN disclosed
US-20220081415-A1 Amino Acid Derivatives for the Treatment of Inflammatory Diseases THE ROSKAMP INST (US) 2022-03-17 US disclosed
US-20220009918-A1 Chemical Compounds GLAXOSMITHKLINE IP DEV LTD (GB) 2022-01-13 US disclosed
CN-113614074-A Amino acid derivatives for the treatment of inflammatory diseases 罗斯坎普研究所 2021-11-05 CN disclosed
US-11149035-B2 Chemical compounds as H—PGDS inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DFVELOPMENT LIMITED (GB) 2021-10-19 US disclosed
EP-3877384-A1 CHEMICAL COMPOUNDS GlaxoSmithKline Intellectual Property Development Ltd (GB) 2021-09-15 EP disclosed
CN-102573845-A Novel dicarboxylic acid linked amino acid and peptide prodrugs of opioids and uses thereof SHIRE LLC 2012-07-11 CN disclosed
EP-2413937-A1 NOVEL DICARBOXYLIC ACID LINKED AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF Shire LLC (US) 2012-02-08 EP disclosed
WO-2011071951-A2 N-ACYLOXYSULFONAMIDE AND N-HYDROXY-N-ACYLSULFONAMIDE DERIVATIVES JOHNS HOPKINS UNIVERSITY (US) 2011-06-16 WO disclosed
US-20110144067-A1 N-Acyloxysulfonamide and N-Hydroxy-N-Acylsulfonamide Derivatives THE JOHNS HOPKINS UNIVERSITY 2011-06-16 US disclosed
US-20100286186-A1 NOVEL DICARBOXYLIC ACID LINKED AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF SHIRE LLC (US) 2010-11-11 US disclosed
WO-2010112942-A1 NOVEL DICARBOXYLIC ACID LINKED AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF SHIRE LLC (US) 2010-10-07 WO disclosed
EP-0642530-A1 DERIVATIVES OF DOLASTATIN BASF Aktiengesellschaft (DE) 1995-03-15 EP disclosed
US-4945168-A Method of preparing aryl-(1-phthalimido)-alkyl ketones DEGUSSA AKTIENGESELLSCHAFT (DE) 1990-07-31 US disclosed
EP-0304018-A2 Process for the preparation of aryl-(1-phthalimido)alkyl ketones Degussa Aktiengesellschaft (DE) 1989-02-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11149035-B2 Chemical compounds as H—PGDS inhibitors HPGDS, PTGS1, PTGIS TP53 4787/4885ALDH1A1 918/4885LMNA 925/4885
US-20140235636-A1 N-ACYLOXYSULFONAMIDE AND N-HYDROXY-N-ACYLSULFONAMIDE DERIVATIVES TNNI3, TNNT2, TNNC1 TP53 814/4885ALDH1A1 698/4885LMNA 762/4885
US-20220009918-A1 Chemical Compounds HPGDS, PTGS1, PTGER1 TP53 4678/4885ALDH1A1 144/4885LMNA 1339/4885
US-20100286186-A1 NOVEL DICARBOXYLIC ACID LINKED AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF VIP, OPRL1, OPRK1 TP53 3114/4885ALDH1A1 1313/4885LMNA 4259/4885
US-20160046570-A1 N-ACYLOXYSULFONAMIDE AND N-HYDROXY-N-ACYLSULFONAMIDE DERIVATIVES TNNI3, TNNT2, TNNC1 TP53 814/4885ALDH1A1 698/4885LMNA 762/4885
US-20110144067-A1 N-Acyloxysulfonamide and N-Hydroxy-N-Acylsulfonamide Derivatives TNNI3, TNNT2, TNNC1 TP53 814/4885ALDH1A1 698/4885LMNA 762/4885
US-20220081415-A1 Amino Acid Derivatives for the Treatment of Inflammatory Diseases NFKBIA, NFRKB, IKBKG TP53 1553/4885ALDH1A1 4214/4885LMNA 2065/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.